Showing results 1 to 2 of 2
Title | Author(s) | Issue Date | |
---|---|---|---|
2017 | |||
A phase I/II study of foretinib, an oral multikinase inhibitor targeting MET, RON, AXL, TIE-2, and VEGFR in advanced hepatocellular carcinoma (HCC) Proceeding/Conference:Journal of Clinical Oncology | 2012 |